Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 4—April 2022
Dispatch

In Vitro Confirmation of Artemisinin Resistance in Plasmodium falciparum from Patient Isolates, Southern Rwanda, 2019

Welmoed van LoonComments to Author , Rafael Oliveira, Clara Bergmann, Felix Habarugira, Jules Ndoli, Augustin Sendegeya, Claude Bayingana, and Frank P. Mockenhaupt
Author affiliations: Charité–Universitaetsmedizin, Berlin, Germany (W. van Loon, R. Oliveira, C. Bergmann, F.P. Mockenhaupt); University Teaching Hospital of Butare, Butare, Rwanda (F. Habarugira, J. Ndoli, A. Sendegeya); King Faisal Hospital, Kigali (A. Sendegeya); University of Rwanda, Kigali, Rwanda (C. Bayingana)

Main Article

Figure 2

IC50 values for dihydroartemisinin for an artemisinin-susceptible, K13 WT Plasmodium falciparum strain (NF54) and in 4 P. falciparum patient isolates from Rwanda with K13 mutations. Indicated error bars display the mean + SE. p values were determined by Student t-test. IC50, 50% inhibitory concentration; K13, kelch 13; WT, wild-type.

Figure 2. IC50 values for dihydroartemisinin for an artemisinin-susceptible, K13 WT Plasmodium falciparum strain (NF54) and in 4 P. falciparum patient isolates from Rwanda with K13 mutations. Indicated error bars display the mean + SE. p values were determined by Student t-test. IC50, 50% inhibitory concentration; K13, kelch 13; WT, wild-type.

Main Article

Page created: January 27, 2022
Page updated: March 19, 2022
Page reviewed: March 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external